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ABSTRACT 
The aim of the present study was to assess the efficacy and safety of olanzapine in the 
treatment of schizophrenic patients. 27 patients were randomly assigned to treatment with olanzapine 
or haloperidol over 12 weeks. The primary efficacy measure was the mean change from baseline to 
endpoint in total scores on the Brief Psychiatric Rating Scale (BPRS) and assessing treatment 
emergent adverse events. Secondary measures were positive symptoms, negative symptoms, general 
psychopathology depression, anxiety and quality of life. Compared to haloperidol, olanzapine had 
equal effect in improving overall psychopathology, positive symptoms, and severity of schizophrenic 
illness. Olanzapine showed supehor improvement on negative symptoms and secondary depressive 
features. Commonest side effects were weight gain, sleepiness and increased duration of sleep. 
Olanzapine is effective in improving overall psychopathology including positive symptoms, negative 
and secondary depressive features in Indian patients with schizophrenia and it is safe and well 
tolerated at dosage between 5 to 20 mg/day 
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Schizophrenia is a hetrogeneous condition 
that includes positive, disorganized, dysphoric and 
negative symptoms. Evidence linking these 
symptoms to multiple brain regions is increasing 
suggesting the underlying disruption of one or more 
fundamental neural circuits (Andreason,1953). 
Furthermore, in contrast to earlier theories (e.g. 
one transmitter, one locus), broad ranges of 
neurotransmitters at multiple loci are now 
implicated (Carlsson,1995). 
Conventional antipsychotic agents do not 
exert therapeutic effects against all domains of 
schizophrenic pathology e.g. negative or deficit 
features (Liberman, 1993). Furthermore, neuroleptic 
induced adverse events contribute to rates of non-
compliance approaching 50% (Kane,1987). 
Alternative approaches, implicating other 
neurotransmitter system have led to the 
development of novel antipsychotic drugs such 
as olanzapine polymorph (Meltzer,1991). 
Olanzapine is an atypical antipsychotic with 
a broad binding and pharmacological profile 
(Bymaster et al.,1996). In vitro receptor binding 
studies showed a high affinity for dopamine D2, 
D3and D4 receptors; all 5-HT2 receptor subtypes 
and the 5-HT6 receptor; muscarinic receptors, 
especially the M, subtypes; and a1 - adrenergic 
receptors. In vivo studies showed that olanzapine 
had potent activity at D2 and 5HT2A receptors, but 
much less activity at D, and muscarinic receptors, 
and that it inhibited dopaminergic neurons in the 
A10 but not the A9 tract, suggesting that this agent 
will not cause extrapyramidal side effects (EPS). 
Microdialysis studies showed that olanzapine 
increased the extracellular levels of norepinephrine 
and dopamine, but not 5-HT, in the prefrontal 
cortex, and increased extracellular dopamine 
levels in the neostriatum and neucleus 
accumbens, areas of the brain associated with 
scizophrenia. Studies of gene expression showed 
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that olanzapine 10 mg/kg also increased FOS 
expression in the prefrontal cortex, the dorsolateral 
striatum, and the nucleus accumbens. These 
findings are consistent with the effectiveness of 
olanzapine on both negative and positive 
symptoms and suggest that, with careful dosing, 
olanzapine should not cause EPS (Bymaster et 
al.,1996). 
In a series of double blind controlled trials 
in patients with schizophrenia and schizoaffective 
disorder, olanzapine appeared superior to 
conventional dopamine D, antagonist, haloperidol 
on measures of overall psychotic symptoms, 
negative symptoms, comorbid mood symptoms 
and quality of life (Tollefson etal.,1998; Beasley 
et al ,1997, Tollefson et al ,1997, Beasley et 
al.,1996) However, there is paucity of studies from 
India evaluating efficacy and safety of olanzapine. 
Transcultural including racial variations in 
psychopharmacological research in a nascent 
area, necessitating clinical trials of drugs in diverse 
populations 
The present study was part of a 
multicentered clinical trial carried out at 7 centres 
to assess the safety and efficacy of olanzapine 
vs haloperidol in the treatment of schizophrenic 
patients in India. In this report, data from only one 
centre is being presented. 
MATERIAL AND METHOD 
Patients were selected from those who 
were attending outpatient facility or admitted in 
the ward of Psychiatry Department of PGIMER, 
Chandigarh 
This was an open-label study of total 30 
male/female inpatients and out patients between 
18 to 65 years of age who met the DSM-IV criteria 
for schizophrenia (APA.1994) and had an initial 
score of atleast 3 on the CGI Severity Scale 
(Guy, 1976) After describing various aspects of 
the study to the patients/guardians, informed 
consent was obtained 
Study period I was the screening and 
washout period of the study Study period II was 
the therapy period of the study and consisted of 
12 weeks of open label therapy. At visit I (study 
period I) detailed history and psychiatric 
examination of the patients was done and clinical 
laboratory tests (all tests of clinical chemistry, 
hematology and hepatitis screen) were performed. 
Patients who were found to be positive for hepatitis 
surface antigen (HBs Ag), IgM fraction of the 
hepatitis core antibody (anti-HBc[lgM]) or had 
jaundice, current agranulocytosis (absolute 
neutrophil count <500 mm
3) were excluded from, 
the study Patients who qualified all the inclusion 
criteria at visit 2 were randomly assigned to the 
treatment group of either olanzapine or haloperidol. 
Either drug could be subsequently increased by 
10 mg/day to 20 mg/day or decreased to a 
minimum of 5 mg/day as clinically warranted. 
Patients were assessed at 1 week interval from 
visit 2 to visit 6 and then after every 2 weeks from 
visit 6 to 10. 
The primary efficacy measure was the mean 
change from baseline to end point on Brief 
Psychiatric Rating Scale's (BPRS) total score 
derived from Positive And Negative Syndrome 
Scale (PANSS Kay et al.,1986), Scale for the 
Assessment of Negative Symptoms (SANS) 
(Andreason,1983), Montgomery - Asberg 
Depression Rating Scale (MADRS) (Montgomery 
and Asberg, 1979), Hamilton-Anxiety Scale (HAM-
A) (Hamilton, 1959), Clinical Global Impression 
Scale (CGI) (Guy, 1976), and Quality of Life Scale 
(QOL)(Heinrichetal,1984). 
Treatment emergent adverse events 
including extrapyramidal symptoms were 
assessed by UKU Side Effect Rating Scale 
(Lingjaerde et al.,1987), Simpson Angus Scale 
(Simpson and Angus, 1970), Barnes Akathisia 
Rating Scale (Barnes,1989), and by changes in 
vital signs and laboratory tests. 
RESULTS 
A total of 30 patients were included in the 
study. Of those 30, 27 patients were randomized 
to treatment group. Two patients were excluded 
from the study as one patient was found to be 
positive for Anti-HBc (IgM) and the other patient 
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was positive on HBs Ag. The third patient was 
excluded from the study because she had tardive 
dystonia and she got randomized to haloperidol, 
so the physician decided against exposing the 
patient to this study drug. 
10 patients were randomized to haloperidol 
and 17 patients were randomized to olanzapine. 
In haloperidol group 7 patients completed the 
protocol, 2 patients were lost to follow up and 1 
patient was dropped from the study as he 
developed severe side effects. In olanzapine group 
16 patients completed the trial as per protocol 
and 1 patient was lost to follow up. Thus, 23 
patients completed the protocol, 7 in haloperidol 
group and 16 in olanzapine group. 
Results revealed that improvements in 
mean scores from baseline to the endpoint of Brief 
Psychiatric Rating Scale (BPRS) total score 
extracted from Positive and Negative Syndrome 
Scale (PANSS) was significant in both the groups: 
olanzapine group (t-5.87 p<01), as well as 
haloperidol group (t-2.49 p<05). On BPRS positive 
score too both the groups have shown significant 
mean improvement from baseline to the endpoint. 
However, on BPRS - Negative and BPRS - Anxiety 
subscales, haloperidol group showed no significant 
mean improvement whereas olanzapine group had 
shown significant improvement on BPRS negative 
and BPRS anxiety subscales (Table 1 and 2). 
On positive symptoms, negative symptoms 
and general psychopathology subscales of 
Positive and Negative Syndrome Scale (PANSS) 
both the groups i.e. olanzapine group and 
haloperidol group had shown significant mean 
improvement from baseline to the endpoint (Table 
1 and 2). On overall psychopathology, based on 
the CGI Severity Scale, both the groups have 
shown significant improvement (OLZt=5.96 
p<0.01,HALt=3.87p<0.05). 
On Montgomery - Asberg Depression 
Rating Scale (MADRS) and Hamilton - Anxiety 
Scales (HAM-A), haloperidol group showed no 
significant mean improvement from baseline to 
endpoint, whereas, olanzapine group showed 
significant improvement on both MADRS and 
HAM-A. There was no significant 
improvement on Global Rating of Affective 
TABLE 1 
BASELINE TO END-POINT SCORES OF RATINGS 
SCALES IN OLANZAPINE GROUP 
BPRS-total 
BPRS-positive 
BPRS-negative 
BPRS-anxiety 
PANSS-positive 
PANSS-negative 
Olanz 
Base 
M 
23.31 
912 
5.06 
4.19 
1937 
21.87 
PANSS-GenPsyPath 36.56 
MADRS 
HAM-A 
CGI-severity 
Affecting flattening 
Alogia 
Avoilition 
Anhedonia 
Attention 
SANS total score 
Barnes akathisia 
Simpson-Angus 
Quality of Life 
(total score) 
9.12 
8.31 
4.68 
1.69 
1.37 
2.31 
2.87 
1.68 
32.94 
0.44 
1.37 
47.0 
* Significant at 0.05 level 
apine group (n= 
me 
SD 
9.94 
5.35 
4.14 
220 
7.06 
7.69 
9.46 
5.15 
5.13 
0.89 
1.54 
1.26 
1.45 
1.31 
1.63 
19.69 
1.09 
1.71 
24.64 
** Significant at 0.01 level 
a TABLE 2 
= 16) 
End point 
M 
950 
3.75 
3.12 
1.31 
11.44 
15.62 
25.12 
3.00 
2.31 
3.19 
1.19 
1 06 
1.50 
1.81 
0.94 
21.87 
0.00 
0.75 
51.19 
SD 
7.06 
4.25 
3.42 
1.66 
4.11 
7.93 
525 
2.42 
2.47 
0.98 
1 28 
1.12 
1.32 
1.38 
1.12 
t-ratio 
5.87" 
4.87" 
2.64" 
549" 
4.06" 
4.52" 
4.83" 
5.68" 
467" 
5.96" 
1 96 
1.31 
2.55" 
3.88" 
2.27* 
19.47 2 95* 
0.00 
1.39 
1.60 
1.40 
23.38 1.03 
BASELINE TO END-POINT SCORES OF RATINGS 
SCALES IN HALOPERIDOL GROUP 
BPRS-total 
BPRS-positive 
BPRS-negative 
BPRS-anxiety 
PANSS-positive 
PANSS-negative 
PANSS-GenPsyPath 
MADRS 
HAM-A 
CGI-severity 
Affecting flattening 
Alogia 
Avoilition 
Anhedonia 
Attention 
SANS total score 
Barnes akathisia 
Simpson-Angus 
Quality of Life 
(total score) 
Haloperidol group (n= 
Base line 
M 
25.00 
7.43 
5.29 
4.86 
19.29 
2329 
3829 
10.29 
9.71 
4.29 
2.14 
2.14 
2.57 
2.71 
2.43 
3971 
0.43 
1.43 
3829 
SO 
4.56 
5.53 
2.50 
2.34 
10.86 
837 
9.45 
4.61 
3.80 
1.11 
1.21 
090 
0.98 
0.76 
0 98 
1205 
079 
2.57 
31 74 
7) 
End point 
M 
12.57 
3.00 
3.57 
2.71 
10.86 
16.86 
26.57 
5.00 
4.57 
2.86 
1.57 
1.14 
1.57 
2.57 
1.71 
27 43 
0.29 
0.86 
49.14 
SO  t-ratio 
13.39 2.49* 
5.51 
2.37 
2.87 
8.49 
8.71 
8.73 
4.58 
4.72 
1.57 
0.97 
1.21 
1.27 
1 72 
1 70 
2.46* 
1.58 
1.73 
2.95* 
254* 
2.87* 
2.29 
1.91 
3.87* 
1.37 
229 
1.73 
0.33 
1 07 
19 48207 
0 49 
1.86 
055 
0.43 
33.88 1 82 
* Significant at 0.05 level 
" Significant at 0.01 level 
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Flattening or Blunting and Alogia subscales of 
scale for the Assessment of Negative Symptoms 
(SANS) in both the groups. On global rating of 
avolition - apathy, anhedonia and attention 
subscales of SANS as well as on SANS total 
score, only olanzapine group had shown 
significant mean change from baseline to endpoint, 
as compared to haloperidol group. 
On Barnes Akathisia Scale and Simpson 
Angus Scale both groups showed no significant 
change from baseline to endpoint. The same was 
true for Quality of Life. Nearly the same trends 
are noticed upon comparing the mean change in 
scores from baseline to endpoint and percentage 
reduction of scores on various rating scales in 
the two study groups, but for Alogia subscale of 
SANS, Barnes Akathisia and QOL (Table 3). 
TABLE 3 
COMPARISON OF MEAN CHANGE AND PERCENTAGE 
REDUCTION OF SCORES 
BPRS-total 
BPRS-positive 
BPRS-negative 
BPRS-anxiety 
PANSS-positive 
PANSS-negative 
PANSS-GenPsyPath 
MADRS 
HAM-A 
CGI-severity 
Affecting flattening 
Alogia 
Avoilition 
Anhedonia 
Attention 
SANS total score 
Barnes akathisia 
Simpson-Angus 
Quality of Life 
(total score) 
Olanzapine 
group 
Mean 
change 
13.81 
5.37 
1.94 
2.87 
7.94 
625 
11.44 
6.12 
6 00 
1.50 
0.50 
031 
081 
1.06 
0.75 
11.06 
0 44 
062 
4.18 
% 
Haloperidol 
group 
Mean  % 
reduction change reduction 
59.2 
58.9 
383 
68.7 
41.4 
286 
31 3 
67 1 
72.2 
32.0 
29.6 
22.7 
351 
37.0 
444 
33.6 
100 0 
454 
89 
12.43 
4.43 
1.71 
2.14 
8.43 
6.43 
11.71 
530 
5 14 
1.43 
0.57 
1.00 
1.00 
0.14 
071 
12.29 
0 14 
057 
10 86 
49.7 
59.6 
32.4 
44.1 
437 
27.6 
30.6 
514 
52.9 
33.3 
26.6 
46.7 
389 
53 
29.2 
309 
334 
399 
284 
Side effects Patients receiving olanzapine did 
not report epileptic seizures, EPS or any side 
effects related to CVS, GIT, dermatology, sexual 
and reproductive functioning Treatment emergent 
side effects i.e. possibly drug-related undesirable 
effects or increase in seventy of baseline 
experiences unrelated to the diagnosis under 
study, after the initiation of the study - drug 
revealed that weight gain was the commonest side 
effect with olanzapine. 
Sleepiness, increased duration of sleep and 
asthenia was observed in more number of patients 
in olanzapine group than haloperidol group. 
Pstients receiving haloperidol also did not 
report epileptic seizures or any side effects related 
to CVS, GIR, dermatology and sexual functioning. 
EPS like rigidity and tremors were reported in more 
number of patients in haloperidol group than 
olanzapine group. Tension/inner unrest was also 
reported more in haloperidol group. 
TABLE 4 
COMPARISON OFTREATMENT 
EMERGENT SIDE-EFFECT 
Asthenia 
Sleepiness 
Tension 
Increase duration of sleep 
Dystonia 
Rigidity 
Hypokinesia 
Tremor 
Akathesia 
Accomodation disturbance 
Increased salivation 
Reduced salivation 
Constipation 
Micturition disturbances 
Weight gain 
Others* 
Olanzapine 
group (N=16) 
N 
7 
8 
-
7 
-
1 
1 
5 
1 
-
3 
4 
5 
1 
13 
5 
% 
43.7 
50 0 
-
43.7 
-
6.2 
62 
31.2 
6.2 
-
18.7 
25.0 
3V2 
62 
81 2 
31.2 
Haloperidol 
group (N=7) 
N 
3 
2 
4 
2 
1 
5 
2 
4 
2 
2 
-
-
-
2 
2 
7 
% 
42.9 
28.6 
57.1 
28.6 
14.3 
71.4 
28.6 
57 1 
28.6 
28.6 
-
-
-
28.6 
28.6 
100 
"Others . Polyuria, orthostatic dizziness, 
nausea, increased sweating and menstrual 
DISCUSSION 
papitations, 
disturbances 
Results of the study indicate that when 
compared to haloperidol, olanzapine had equal 
effect in improving overall psychology, positive 
symptoms and severity of schizophrenic illness. 
In clinical studies conducted in its development, 
olanzapine has shown therapeutic efficacy that 
is at least comparable (and in some instances 
superior) to that of conventional antipsychotic 
drugs (Beasleyetal, 1996,1996a, 1997; Tollefson 
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etal, 1997; Tranetal, 1997). 
On negative symptoms, haloperidol group 
showed significant mean improvement only on 
PANSS - negative subscale and there was no 
significant improvement shown by haloperidol 
group on BPRS - negative, SANS - total, SANS-
subscales. Though there was greater difference 
in mean change of Alogia subscale of SANS in 
haloperidol group than olanzapine group, but it 
did not emerge significant. 
Olanzapine group showed significant 
improvement on BPRS-Negative, PANSS -
Negative Scale, SANS-total and Avolition-apathy, 
Anhedonia and Attention subscales of SANS. 
There was no significant improvement on Affective 
Flattening and Alogia Sub-scales of SANS. 
Significant superior treatment benefits of 
olanzapine relative to haloperidol for negative 
symptoms among patients with schizophrenia 
have been previously reported (Beasley et al.,1997; 
Tollefson etal.,1997; Tollefson and Sanger, 1997). 
Tollefson and Sanger (1997) demonstrated 
that high dose olanzapine had significantly greater 
direct effect than placebo on all SANS dimension 
except anhedonia-asociality. Olanzapine also 
demonstrated a significantly greated direct effect 
than haloperidol on negative symptoms especially 
on the dimentions of affective-flattening and 
avolition-apathy. In our study, olanzapine group 
showed significant improvement on avolition-
apathy but not on dimension of affective flattening. 
Conventional neuroleptics reportedly fail to 
provide a sustained reduction in primary or deficit 
negative symptoms for the majority of patients 
(Kane and Mayeroff,1989; Liberman,1993). 
Negative symptoms impose great suffering on 
patients by impending their rehabilitation and 
psychosocial functioning (Breier et al.,1991). A 
superior negative symptom outcome is a principal 
objective in novel antipsychotic drug development 
(Kirkpatrick & Carpenter, 1995). Meltzer (1995) 
commented that a pleotrophic pharmacology 
(similar to that of olanzapine) may convey a 
therapeutic advantage in the treatment of negative 
symptoms. 
Olanzapine group showed significant 
improvement on MADRS and HAM-A scales 
whereas haloperidol group did not show any 
significant mean improvement on both MADRS 
and HAM-A Scales. Secondary depression, which 
is common in schizophrenia, is predictive of a 
poorer prognosis, including greater difficulty 
reintegrating into society and a higher risk of 
suicide. It has been suggested in the literature 
(Harrow et al, 1994) that neuroleptic drugs may 
actually induce dysphoria. Tollefson et al (1998) 
reported data from a double blind, controlled, 
multicentre trial of treatment of exacerbations of 
schizophrenia or schizo-affective disorder with 
olanzapine versus haloperidol and found significant 
greater improvement in depressive symptoms with 
olanzapine. 
The broad receptor profile of olanzapine may 
contribute to this treatment differeence. The density 
of 5-HT2A receptors, for example, has been 
reported to be increased among patients with 
major depression. Accordingly, olanzapine as a 
potent 5-HT2Aantagonist, may act at these sites, 
similar to the action of the recently approved 
antidepressant nefazodone (Nemrick Luecke et 
al, 1994). The importance of these mood related 
findings is clinically relevant regardless of whether 
they are primary or secondary therapeutic effects 
(Tollefson etal, 1997). 
Studies have also reported that patients 
treated with olanzapine show greater improvement 
in quality of life as compared to patients treated 
with haloperidol (Beasley et al, 1996; Tollefson et 
al, 1997; Tollefson and Sanger, 1997; Beasley et 
al, 1997). However, in the present study olanzapine 
group did not show significant improvement in 
quality of life. 
The most common side effects related to 
olanzapine was weight gain, sleepiness and 
increased duration of sleep. Our results reaffirm 
earlier assertions that compared with traditional 
antipsychotics, olanzapine has a vastly improved 
extra-pyramidal side-effect profile (Casey 1996). 
In conclusion, the analysis indicate that 
olanzapine is effective in the improvement of overall 
psychopathology including positive symptoms, 
negative symptoms and secondary depressive 
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features and it is safe and well tolerated at dosage 
between 5 to 20 mg/day However, small sample 
size and open-label trial are major limitations for 
any definitive assertions. 
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